Colorectal Oncology Research Review, Issue 37

In this issue:

OBELICS: sequential or concomitant dosing of bevacizumab with respect to chemotherapy?
Biosimilar HLX04 equivalent to reference bevacizumab for front-line treatment of recurrent/ metastatic CRC
Does early-onset CRC have more favourable survival outcomes than older-age onset?
Trastuzumab deruxtecan demonstrates meaningful activity in HER2-positive CRC
Relationship of HER2 alteration and microsatellite instability status
Cabozantinib/panitumumab combination shows antitumour activity in RAS wild-type metastatic disease
Concomitant PPI use may impact capecitabine efficacy
More intense follow-up after resection does not improve outcomes in patients with elevated CEA levels
Panitumumab plus trifluridine/ tipiracil may be a therapeutic option for unresectable metastatic CRC
Raltitrexed effective and well tolerated in patients unable to take fluoropyrimidines

Please login below to download this issue (PDF)

Subscribe